TECNALIA will be present at BIOSPAIN 2026, Spain’s leading biotechnology event
Bilbao is hosting one of Europe’s largest gatherings in the biotechnology sector. BIOSPAIN will take place from September 29 to October 1 at the Bilbao Exhibition Centre (BEC), and TECNALIA will once again be participating.
The event will bring together biotechnology and pharmaceutical companies,
startups, technology centers, healthcare organizations, and investors from around
the world with the goal of generating new opportunities for business,
collaboration, and innovation.
At a time when the convergence of biotechnology, digital health, and artificial intelligence is transforming the healthcare sector, TECNALIA will attend BIOSPAIN with a value proposition designed to support companies in developing cutting-edge technologies, from applied research through validation to market transfer.
Smart Medical Devices: Innovation for Smarter Healthcare
One of the main focuses of our participation will be showcasing our capabilities in Smart Medical Devices, a strategic area for the future of healthcare. We develop advanced medical solutions that integrate electronics, sensors, connectivity, artificial intelligence, and data analytics to improve the prevention, diagnosis, monitoring, and treatment of diseases.
We work alongside companies in the sector to transform innovative ideas into safe, effective, and market-ready medical devices, reducing technological risks and accelerating development processes.
In addition, we will showcase the progress of initiatives such as EPID-IA, which focuses on the application of artificial intelligence in the healthcare sector, and A4S, a project aimed at promoting new technological solutions that contribute to more efficient, personalized, and sustainable healthcare.
Advanced Capabilities for the Pharmaceutical and Biotechnology Industries
During BIOSPAIN 2026, we will also showcase our capabilities for pharmaceutical, biotechnology, and medical technology companies seeking a technology partner to accelerate their development and innovation processes.
We cover key activities for the diagnosis, development, and validation of products, including:
• Pharmaceutical development, transfer, and scaling of pharmaceutical products.
• Specialized genetic technologies.
• Microbiome studies.
• Efficacy evaluation of biocides.
• Scientific and technical support for R&D and validation activities.
Thanks to these capabilities, we help companies reduce development times, minimize uncertainties, and move more quickly toward commercializing their innovations.
3D bioprinting: building the future of personalised medicine
As part of the programme at BIOSPAIN 2026, we will be taking part in a round-table discussion on 3D bioprinting, one of the technologies with the greatest potential for transformation within regenerative medicine and the development of new biomedical models.
“The clinical future of bioprinting: from biofabrication technologies to next-generation regenerative therapies” will take place on 30 September at 9.30 am. At this session, we will share our experience in developing solutions based on biofabrication and bioprinting for applications in tissue engineering, advanced models for biomedical research and new strategies for personalised medicine.
Attendees will be able to gain first-hand insight into the capabilities TECNALIA is developing in this field, as well as the opportunities these technologies offer to accelerate research, improve pre-clinical validation and move towards more precise treatments tailored to the needs of each patient.
BIO4 Campus
During the BIOSPAIN event, our Health team will present TECNALIA2BIO4: a project aimed at strengthening the capabilities of organisations based at the BIO4 Campus, both in the fields of research and development and in those of commercialisation and business.
The conference ‘Science2Industry Bridging: internationalisation opportunities for Spanish biotechnology companies in Serbia’, will take place on 30 September at 1.00 pm as part of BIOSPAIN and aims to introduce Spanish companies to the business, collaboration and export opportunities emerging in Serbia, particularly around the BIO4 Campus, one of the most significant strategic initiatives in south-eastern Europe in the fields of biotechnology and the bioeconomy.
The session aims to identify Spanish companies interested in entering the Serbian market and to facilitate future business networking initiatives. If you are interested, please contact us by emailing carmen.pastor@tecnalia.com.
Connecting science, technology and the market
BIOSPAIN has established itself as one of the leading international forums for connecting science, industry and investment in the life sciences sector, bringing together thousands of leading professionals and organisations from the global biotech ecosystem.
Throughout the three-day event, our team will be holding meetings with companies, organisations and investors interested in driving forward innovation projects in healthcare, medical technologies, biotechnology and pharmaceutical development.
If you are looking for a technology partner to develop smart medical devices, validate new medicines, make progress in 3D bioprinting or incorporate artificial intelligence into your healthcare solutions, we look forward to seeing you at BIOSPAIN 2026.